The diagnosis of premature ovarian failure is based on the finding of amenorrhoea before age 40 associated with follicle-stimulating hormone levels in the menopausal range. Screening for associated autoimmune disorders and karyotyping, particularly in early onset disease, constitute part of the diagnostic work up. There is no role for ovarian biopsy or ultrasound in making the diagnosis. Management essentially involves hormone replacement and infertility treatment, the most successful being assisted conception with donated oocytes. Embryo cryopreservation, ovarian tissue or oocyte cryopreservation and in vitro maturation of oocytes hold promise in cases where ovarian failure is foreseeable as in women undergoing cancer treatments.

Keywords:
Premature ovarian failure, Amenorrhoea, Follicle-stimulating hormone, Hormone replacement therapy, Infertility treatment
1.
McKinlay SM, Brambilla DJ, Posner JG: The normal menopause transition. Maturitas 1992;14:103–115.
2.
Snieder H, MacGregor AJ, Spector TD: Genes control the cessation of a woman’s reproductive life: a twin study of hysterectomy and age at menopause. J Clin Endocrinol Metab 1998;83:1875–1880.
3.
McKinlay SM: The normal menopause transition: an overview. Maturitas 1996;23:137–145.
4.
Torgerson DJ, Thomas RE, Reid DM: Mothers and daughters menopausal ages: is there a link? Eur J Obstet Gynecol Reprod Biol 1997;74:63–66.
5.
Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N: Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2003;18:199–206.
6.
Coulam CB, Adamson SC, Annegers JF: Incidence of premature ovarian failure. Obstet Gynecol 1986;67:604–606.
7.
Anasti JN: Premature ovarian failure: an update. Fertil Steril 1998;70:1–15.
8.
van Kasteren YM, Hundscheid RD, Smits AP, Cremers FP, van Zonneveld P, Braat DD: Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum Reprod 1999;14:2455–2459.
9.
Conway GS, Payne NN, Webb J, Murray A, Jacobs PA: Fragile X premutation screening in women with premature ovarian failure. Hum Reprod 1998;13:1184–1187.
10.
Laml T, Schulz-Lobmeyr I, Obruca A, Huber JC, Hartmann BW: Premature ovarian failure: etiology and prospects. Gynecol Endocrinol 2000;14:292–302.
11.
Pal L, Santoro N: Premature ovarian failure (POF): discordance between somatic and reproductive aging. Ageing Res Rev 2002;1:413–423.
12.
Goswami R, Goswami D, Kabra M, Gupta N, Dubey S, Dadhwal V: Prevalence of the triple X syndrome in phenotypically normal women with premature ovarian failure and its association with autoimmune thyroid disorders. Fertil Steril 2003;80:1052–1054.
13.
Eggermann T, Meschede D, Schuler H, et al: Premature ovarian failure associated with a small terminal Xq deletion: narrowing the POF1 region down to Xq27.2/Xq27.3-qter. Clin Genet 2005;67:434–437.
14.
Powell CM, Taggart RT, Drumheller TC, et al: Molecular and cytogenetic studies of an X; autosome translocation in a patient with premature ovarian failure and review of the literature. Am J Med Genet 1994;52:19–26.
15.
Davison RM, Fox M, Conway GS: Mapping of the POF1 locus and identification of putative genes for premature ovarian failure. Mol Hum Reprod 2000;6:314–318.
16.
Sala C, Arrigo G, Torri G, et al: Eleven X chromosome breakpoints associated with premature ovarian failure (POF) map to a 15-Mb YAC contig spanning Xq21. Genomics 1997;40:123–131.
17.
Therman E, Laxova R, Susman B: The critical region on the human Xq. Hum Genet 1990;85:455–461.
18.
Schupf N, Zigman W, Kapell D, Lee JH, Kline J, Levin B: Early menopause in women with Down’s syndrome. J Intellect Disabil Res 1997;41:264–267.
19.
Goswami D, Conway GS: Premature ovarian failure. Hum Reprod Update 2005;11:391–410.
20.
Conway GS, Kaltsas G, Patel A, Davies MC, Jacobs HS: Characterization of idiopathic premature ovarian failure. Fertil Steril 1996;65:337–341.
21.
Forges T, Monnier-Barbarino P, Faure GC, Bene MC: Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update 2004;10:163–175.
22.
Hoek A, Schoemaker J, Drexhage HA: Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107–134.
23.
Doldi N, Belvisi L, Bassan M, Fusi FM, Ferrari A: Premature ovarian failure: steroid synthesis and autoimmunity. Gynecol Endocrinol 1998;12:23–28.
24.
Belvisi L, Bombelli F, Sironi L, Doldi N: Organ-specific autoimmunity in patients with premature ovarian failure. J Endocrinol Invest 1993;16:889–892.
25.
Goswami R, Marwaha RK, Goswami D, et al: Prevalence of thyroid autoimmunity in sporadic idiopathic hypoparathyroidism in comparison to type 1 diabetes and premature ovarian failure. J Clin Endocrinol Metab 2006;91:4256–4259.
26.
Bakalov VK, Vanderhoof VH, Bondy CA, Nelson LM: Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod 2002;17:2096–2100.
27.
Kauffman RP, Castracane VD: Premature ovarian failure associated with autoimmune polyglandular syndrome: pathophysiological mechanisms and future fertility. J Womens Health (Larchmt.) 2003;12:513–520.
28.
Melner MH, Feltus FA: Autoimmune premature ovarian failure – endocrine aspects of a T cell disease. Endocrinology 1999;140:3401–3403.
29.
Wheatcroft NJ, Salt C, Milford-Ward A, Cooke ID, Weetman AP: Identification of ovarian antibodies by immunofluorescence, enzyme-linked immunosorbent assay or immunoblotting in premature ovarian failure. Hum Reprod 1997;12:2617–2622.
30.
Nelson LM: Autoimmune ovarian failure: comparing the mouse model and the human disease. J Soc Gynecol Investig 2001;8:S55–S57.
31.
Tong ZB, Nelson LM: A mouse gene encoding an oocyte antigen associated with autoimmune premature ovarian failure. Endocrinology 1999;140:3720–3726.
32.
Tong ZB, Bondy CA, Zhou J, Nelson LM: A human homologue of mouse Mater, a maternal effect gene essential for early embryonic development. Hum Reprod 2002;17:903–911.
33.
Morrison JC, Givens JR, Wiser WL, Fish SA: Mumps oophoritis: a cause of premature menopause. Fertil Steril 1975;26:655–659.
34.
Di Prospero F, Luzi S, Iacopini Z: Cigarette smoking damages women’s reproductive life. Reprod Biomed Online 2004;8:246–247.
35.
Klein P, Serje A, Pezzullo JC: Premature ovarian failure in women with epilepsy. Epilepsia 2001;42:1584–1589.
36.
Sharara FI, Seifer DB, Flaws JA: Environmental toxicants and female reproduction. Fertil Steril 1998;70:613–622.
37.
Lushbaugh CC, Casarett GW: The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 1976;37:1111–1125.
38.
Beerendonk CC, Braat DD: Present and future options for the preservation of fertility in female adolescents with cancer. Endocr Dev 2005;8:166–175.
39.
Madsen BL, Giudice L, Donaldson SS: Radiation-induced premature menopause: a misconception. Int J Radiat Oncol Biol Phys 1995;32:1461–1464.
40.
Morice P, Juncker L, Rey A, El-Hassan J, Haie-Meder C, Castaigne D: Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril 2000;74:743–748.
41.
Byrne J, Fears TR, Gail MH, et al: Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788–793.
42.
Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN: Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003;88:5307–5314.
43.
Hascalik S, Celik O, Sarac K, Hascalik M: Transient ovarian failure: a rare complication of uterine fibroid embolization. Acta Obstet Gynecol Scand 2004;83:682–685.
44.
Nelson HD: Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004;7:1610–1620.
45.
Henzl MR, Loomba PK: Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med 2003;48:525–540.
46.
Scarabin PY, Oger E, Plu-Bureau G: Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–432.
47.
Jones SC: Subcutaneous estrogen replacement therapy. J Reprod Med 2004;49:139–142.
48.
Suckling J, Lethaby A, Kennedy R: Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003;4:CD001500.
49.
Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243–3253.
50.
Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–427.
51.
Davis SR, Burger HG: The role of androgen therapy. Best Pract Res Clin Endocrinol Metab 2003;17:165–175.
52.
Arlt W: Androgen therapy in women. Eur J Endocrinol 2006;154:1–11.
53.
van Kasteren YM, Schoemaker J: Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999;5:483–492.
54.
Rotsztejn DA, Remohi J, Weckstein LN, et al: Results of tubal embryo transfer in premature ovarian failure. Fertil Steril 1990;54:348–350.
55.
Abdalla HI, Baber RJ, Kirkland A, Leonard T, Studd JW: Pregnancy in women with premature ovarian failure using tubal and intrauterine transfer of cryopreserved zygotes. Br J Obstet Gynaecol 1989;96:1071–1075.
56.
Silber SJ, Lenahan KM, Levine DJ, et al: Ovarian transplantation between monozygotic twins discordant for premature ovarian failure. N Engl J Med 2005;353:58–63.
57.
Poirot C, Vacher-Lavenu MC, Helardot P, Guibert J, Brugieres L, Jouannet P: Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod 2002;17:1447–1452.
58.
Donnez J, Dolmans MM, Demylle D, et al: Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405–1410.
59.
Borini A, Bonu MA, Coticchio G, Bianchi V, Cattoli M, Flamigni C: Pregnancies and births after oocyte cryopreservation. Fertil Steril 2004;82:601–605.
60.
Lucena E, Bernal DP, Lucena C, Rojas A, Moran A, Lucena A: Successful ongoing pregnancies after vitrification of oocytes. Fertil Steril 2006;85:108–111.
61.
Rao GD, Tan SL: In vitro maturation of oocytes. Semin Reprod Med 2005;23:242–247.
62.
Cha KY, Koo JJ, Ko JJ, Choi DH, Han SY, Yoon TK: Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril 1991;55:109–113.
63.
Liao KL, Wood N, Conway GS: Premature menopause and psychological well-being. J Psychosom Obstet Gynaecol 2000;21:167–174.
64.
Schmidt PJ, Cardoso GM, Ross JL, Haq N, Rubinow DR, Bondy CA: Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. JAMA 2006 22; 295:1374–1376.
65.
Groff AA, Covington SN, Halverson LR, Fitzgerald OR, Vanderhoof V, Calis K, Nelson LM: Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril 2005;83:1734–1741.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.